Should you build or buy Label & Artwork Management?

Label and artwork management software routes packaging and label artwork through review, approval, version control and regulatory sign-off, with deterministic text and pixel comparison against controlled phrase libraries. Regulatory affairs, packaging and quality teams at pharma, food and consumer goods companies use it to prevent labeling errors that trigger recalls.

Buy the control plane: workflow, version of record, audit history and proofing integration. Configure the routes, signers and content rules to your regulatory and retailer requirements rather than building the system. Use a general workflow or DAM tool only when volumes are modest and you already have a platform team, and treat 21 CFR Part 11 as an implementation outcome you validate, not a checkbox the vendor supplies.

Build it, buy it, or bridge?

⚒ Build it
✓ Buy it
➔ Bridge
Cost shape
A full lifecycle vendor deployment for a large CPG can run into the low millions over three years.
That figure is the vendor cost itself; all four major platforms price by quote.
Buy the control plane; skip custom builds entirely since even the vendor path is costly.
Time to value
Narrow homegrown label-printing or change-request tools exist, but not a full lifecycle platform.
AstraZeneca's validated Loftware Smartflow rollout took 11 months and now handles 10,000-plus changes yearly.
Buy the workflow and proofing core; add a DAM only if volumes justify it.
Differentiation captured
None in the workflow. Approval routing and version control look the same at every regulated maker.
Your brand lives in the artwork content, phrase libraries and market rules, not in who approves it.
Vendor owns the control plane; you own the phrase libraries and regulatory content within it.
AI feasibility today
AI-assisted proofing exists, but the only named self-builds are narrow label-printing systems, not full lifecycle tools.
AI feasibility stays low; vendors still hold deterministic pixel comparison and Part 11 evidence.
Use AI tools for early-draft proofreading only, then rely on the vendor's deterministic comparison for sign-off.
Who it fits
Nobody at enterprise scale. Two named homegrown systems were replaced for maintenance cost.
Any regulated food, pharma or consumer goods company managing labels across markets.
Companies with modest volume and an existing platform team running a general workflow tool.

When building makes sense

The build path here is thin and mostly cautionary. Some manufacturers run narrow homegrown tools, such as a label-printing system layered on an ERP or a workflow tool layered on SharePoint for change-request routing, and both are narrow: label printing or change-request routing, not full lifecycle management with deterministic comparison and Part 11 evidence. Medical device makers have run homegrown label systems and later replaced them with a vendor platform once change maintenance became a bottleneck their own teams could not absorb. No named enterprise runs a self-built end-to-end artwork approval and proofreading platform at scale. A general workflow or DAM tool is defensible only when volumes are modest and a platform team already exists to own it, and even then, treat 21 CFR Part 11 as validation work you still have to do yourself.

When buying makes sense

Buy the control plane: workflow, version of record, audit history and proofing integration. Named production deployments run a purchased platform configured to that company's routes, signers and content rules rather than a homegrown system; Teleflex, for example, runs its artwork process on Kallik's platform integrated with its Oracle Agile PLM system rather than a bespoke build. GlobalVision's deterministic text and pixel comparison is what catches the error a human proofreader misses, and that comparison engine is exactly what vendors maintain and improve. Configure the routes and phrase libraries to your own regulatory and retailer requirements, and treat Part 11 compliance as validation work you complete in your own deployment, whatever the vendor supplies. A validated enterprise rollout is a multi-month project even with a vendor platform doing the heavy lifting, so budget the implementation timeline accordingly.

The desk read

Build-versus-buy analysis for Label & Artwork Management is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.

Representative vendors Esko WebCenterGlobalVision + 5 more, listed in the full index

Frequently asked

Why do companies that built their own label systems switch to vendors?

Representative vendors include Esko WebCenter, GlobalVision. B4 Pro includes the category score and the full vendor list.

Is GlobalVision enough on its own, or do we need a lifecycle platform too?

GlobalVision is proofreading and comparison only. A buyer wanting full lifecycle management, version control and approval routing needs a second system like Loftware, Esko WebCenter or Kallik alongside it, since GlobalVision does not manage the workflow itself.

Does buying a platform satisfy 21 CFR Part 11 automatically?

No. The platform provides the audit trail, e-signature and access-control features Part 11 requires, but your own validated deployment, not the vendor's software alone, is what demonstrates compliance to an FDA auditor.

How long does an enterprise artwork management rollout actually take?

Expect months, not weeks. A validated rollout that integrates with an existing PLM or ERP system, like Teleflex's Kallik deployment tied to Oracle Agile PLM, needs time for data mapping and validation before it reaches full production volume.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.